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Mutations that accumulate in self-renewing hematopoietic stem and progenitor
cells (HSPCs) can cause severe blood disorders. Tomodel such disorders in mice,
we developed a CRISPR/Cas9/adeno-associated virus (AAV)-based system to
knock in and repair genes by homologous recombination in mouse HSPCs.
Here, we provide a step-by-step protocol to achieve high efficiency of gene
knockin in mouse HSPCs, while maintaining engraftment capacity. This
approach enables the functional study of hematopoietic disease mutations in
vivo, without requiring germline mutagenesis.
For complete details on the use and execution of this protocol, please refer to
Tran et al. (2019).BEFORE YOU BEGIN
Experimental Design Considerations
Timing: 1–2 weeks
1. To achieve efficient homologous recombination (HR) events in mouse HSPCs, a
specific single-guide RNA (sgRNA) with high editing efficiency is required. We
use the CrispRGold program (https://crisprgold.mdc-berlin.de) to design spe-
cific sgRNAs and to predict potential off-targets (Chu et al., 2016a). Several spe-
cific sgRNAs should be designed per targeted sequence. Editing efficiencies of
all sgRNAsmust be validated bymeasuringmismatchedDNA heteroduplexes us-
ing the T7 endonuclease I assay (Guschin et al., 2010) and Sanger sequencing of
PCR products for at least 2 primary blood cell types, such as B and T cells. sgRNAs
can be ordered as chemically modified or unmodified forms from IDT, Synthego
or alternative suppliers.
2. The optimal design of the donor template is essential for efficient HR in mouse
HSPCs. The donor template includes 5’, 3’ homology arms and desired modified
gene sequences. The length of the homology arms is dependent on theSTAR Protocols--, 100028,--, 2020 ª 2020 The Authors.
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packaging capacity of the AAV genome is a limitation for designing the donor
template as the maximal length of AAV-based donor templates should not
exceed 4.5kb. In case no reporter gene is used, a restriction enzyme recognition
site should be added to the modified gene sequences through introducing silent
mutations that can be used to quantify HR efficiency.
3. In order to quantify HR and non-homologous end joining (NHEJ) events in the tar-
geted loci by PCR amplification and sequencing, forward or reverse primers, or
both must be designed outside of the 5’ or 3’ homology arms. Primer sets outside
of the homology arms should exclude the possibility of donor template amplifica-
tion. For amplifying large PCR fragments (>2.0 kb), we use LongAmp Polymerase.
4. Mouse strains: We have successfully performed reporter knockins in HSPCs isolated
either from C57BL/6 or Cas9 transgenic mice as reported previously (Chu et al.,
2016b). The targeted HSPCs can be transplanted into sublethally irradiated
Rag2/cg/ (Tran et al., 2019) or lethally irradiated immunocompetent mice (Du-
ran-Struuck et al., 2008) to assess engraftment efficiency of the targeted HSPCs.
5. Healthy and low passage HEK293T cells are critical for a high yield of AAV. The
HEK293T cells used for AAV production are maintained below 80% confluence
and passaged less than 15 times. After thawing, HEK293T cells should be kept
in culture for at least one passage before seeding for AAV production.
KEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
TrueStain FcX (anti-mouse CD16/32,
clone 93)
BioLegend Cat#101320
RRID:AB_1574973
BV785 anti-mouse Ly6A/E (Sca1) (clone
D7)
BioLegend Cat#108139
RRID:AB_2565957
APC anti-mouse CD117 (c-Kit) (clone
2B8)
BioLegend Cat#105812
RRID:AB_313221
APC/Cy7 anti-mouse CD48 (clone
HM48-1)
BioLegend Cat#103431
RRID:AB_2561462
BV605 anti-mouse CD150 (clone TC15-
12F12.2)
BioLegend Cat#115927
RRID:AB_11204248
PE/Cy7 anti-mouse B220 (clone RA3-
6B2)
BioLegend Cat#103221
RRID:AB_313004
PE/Cy7 anti-mouse CD3e (clone 145-
2C11)
BioLegend Cat#100319
RRID:AB_312684
PE/Cy7 anti-mouse Gr-1 (clone RB6-
8C5)
BioLegend Cat#108415
RRID:AB_313380
PE/Cy7 anti-mouse Ter-119 (clone TER-
119)
BioLegend Cat#116221
RRID:AB_2137789
PE/Cy7 anti-mouse CD11b (clone M1/
70)
BioLegend Cat#101215
RRID:AB_312798
PE/Cy7 anti-mouse CD11c (clone N418) BioLegend Cat# 117317
RRID:AB_493569
Bacterial and Virus Strains
TOP10 Invitrogen Cat#C404003
AAV-DJ Cell Biolabs Cat#VPK-400-DJ
Biological Samples
Mouse primary cells MDC Berlin, Germany N/A
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins
DAPI Sigma Aldrich Cat#D9542
Sodium azide (NaN3) Sigma Aldrich Cat#S8032-25G
Sodium chloride (NaCl) Carl Roth Cat#3957.2
Potassium bicarbonate (KHCO3) Sigma Aldrich Cat# 237205
Potassium chloride (KCl) Sigma Aldrich Cat#60128-1Kg-F
DOC (sodium deoxycholate) Sigma Aldrich Cat#D6/50-25G
Magnesium chloride (MgCl2) ROTH Cat#KK363
Sodium succinate( C4H4Na2O4) SERVA (Germany) Cat#14972
EDTA ROTH Cat#8040.2
Sodium phosphate monobasic
(NaH2PO4)
Sigma Aldrich Cat# S8282
Sodium phosphate dibasic (Na2HPO4) Sigma Aldrich Cat# S7907
Tris-HCl ROTH Cat#9090.3
Agarose Biozym Cat#840004
Ethidium bromide solution Invitrogen Cat#15585-011
Benzonase Nuclease 250 U/mL Millipore Cat#:71205-3
RNase-free DNase I Qiagen Cat#:79254
SpCas9 protein MDC Berlin, Germany N/A
SpCas9 protein IDT Cat#1081059
99% Ethanol MDC Berlin, Germany N/A
StemSpan SFEM II Stem Cell
Technologies
Cat#09655
DMEM+/+ Gibco Cat#41966052
Opti-MEM Gibco Cat# 31985047
1 M HEPES Gibco Cat#15630056
PBS pH 7.2 Gibco Cat#20012019
BSA, Albumin Fraction V Carl Roth Cat#8076.3
FBS Sigma Aldrich Cat#F7524-500mL
Gentamycin Lonza Cat#17-519L
OptiPrep Density Gradient Medium Sigma Aldrich Cat#D1556-250mL
Mouse recombinant TPO Peprotech Cat#315-14
Mouse recombinant SCF Peprotech Cat#250-03
Mouse recombinant Flt3-ligand Peprotech Cat#250-31L
Human recombinant IL-11 Peprotech Cat#200-11
Quick ExtractDNA Extraction Solution
1.0
Lucigen Cat#QE09050
Phenol Red solution Sigma Aldrich Cat#P0290
10% Pluronic F-68 Gibco Cat#24040-032
Polyethylenimine (PEI) Polysciences Cat#23966-1
Trysin-EDTA Sigma Cat#T3924-100mL
Critical Commercial Assays
Anti-mouse Sca1 MicroBead Kit
(VioBright FITC)
Miltenyi Biotec Cat#130-123-124
LongAmp PCR Master Mix New England Biolabs Cat#M0533L
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
KOD Hot Start DNA Polymerase Millipore Cat#71086-3
p.JET TOPO cloning Kit Thermo Fischer Cat#K1231
T7 endonuclease I NEB Cat#M0302S
CellTrace Violet Invitrogen Cat#C34557
TaqMan Universal PCR MasterMix Applied Biosystems Cat#4324018
Experimental Models: Cell Lines
HEK293T ATCC ATCCCRL-3216
Experimental Models: Organisms/Strains
C57BL/6 Taconic C57BL/6NTac
R26-Cas9iGFP Chu et al., 2016b N/A
Rag2/cg/ Taconic N/A
Oligonucleotides
Chemically modified and unmodified
sgRNAs
Synthego or IDT N/A
AAV ITR primers
FOR 50-CGGCCTCAGTGAGCGA-30
REV 50-
GGAACCCCTAGTGATGGAGTT-30
Eurofins N/A
AAV ITR probe
50-CACTCCCTCTCTGCGCGCTCG-30
Eurofins N/A
Recombinant DNA
AAV-DJ Rep/Cap plasmid Cell Biolabs Cat#VPK-400-DJ
AAV-helper plasmid Cell Biolabs Cat#VPK-400-DJ
pAAV-DJ plasmid Cell Biolabs Cat#VPK-400-DJ
pAAV-mCherry genome plasmid Tran et al., 2019 N/A
Software and Algorithms
FlowJo LLC https://www.flowjo.com/
CrispRGold Chu et al., 2016a https://crisprgold.
mdc-berlin.de
ImageJ NIH imageJ https://imagej.nih.gov/ij
Other
Dry ice MDC Berlin, Germany N/A
PCR Stripe Tubes Axygen Cat#PCR-0208-CPC
MicroAmp Fast 96-well reaction plate
(0.1 mL)
Applied Biosystems Cat#4346907
MicroAmp Clear Adhesive Film Applied Biosystems Cat#4306311
Beckmann Optima L-80 XP
Ultracentrifuge
Beckmann Coulter N/A
StepOnePlus Real-time PCR system Applied Biosystems N/A
Mastercycler nexus X2 Eppendorf N/A
Amaxa 4D Nucleofector Lonza N/A
16-well NucleocuvetteTM Strips Lonza Cat#V4XP-3032
BD Filcon, Sterile, Cup-Type BD Biosciences Cat#340629
Type 70 Ti Fixed-Angle Titanium Rotor Beckmann Coulter Cat#337922
OptiSeal tube adapters Beckmann Coulter Cat#361669
150 mm petri dishes Sarstedt Cat#82.1473
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
50 mL Polystyrene Conical Tube Corning Cat#352070
15 mL Polystyrene Conical Tube Corning Cat#352096
Optiseal Polypropylene Centrifugation
Tubes
Beckmann Coulter Cat#361625
Amicon Ultra -15 Centrifugal Units-
100K
Merck Millipore Cat#UFC910008
Slide-A-Lyzer Dialysis Cassette 10.000
MWCO
Thermo Scientific Cat#66811
0.45 mm PES filter Jet Biofill Cat#FCA-406-030
0.22 mm PES filter small Santa Cruz
Biotechnology
Cat#Sc-516079
0.22 mm PES filter Whatman Life Sciences Cat#10462200
50 mm Filter mesh BD Cat#340632
2 10 3 80 mm 14G 3 3 1/8 inch needle Braun Cat#4665473
1.2 38 mm 18Gx 1 1/2 inch needle Terumo Cat#AN*1838S1
0.9 3 40 mm 20G 1 1/2 inch needle Braun Cat#4657519
0.5 3 16 mm 25G 5/8 inch needle Henry Schein Cat#9003629
0.4 3 19 mm 27G 1 1/2 inch needle BD Cat#302200
1 mL syringe Braun Cat#9161406V
5 mL syringe Braun Cat#4606051V
10 mL syringe Braun Cat#4606108V
20 mL syringe Braun Cat#4606205V
Kimwipe Tissue Kimwipe Cat#7552
Cell Scraper 245 mm length Carl Roth Cat#EKX9.1
LS Columns Miltenyi Biotec Cat#130-042-401
MS Columns Miltenyi Biotec Cat#130-042-201
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Reagent Final Concentration (mM) Volume
NHCl4 (powder) 155 8.3 g
KHCO3 (powder) 10 1 g
EDTA (powder) 0.1 0.037 g
ddH2O n/a 1 L
Total n/a 1 L
Mix to dissolve and adjust pH to 7.5 with HCl. Autoclave and store this solution at 4C for 6 months.
FACS Buffer
Reagent Final Concentration (%) Volume
BSA (powder) 1 5 g
NaN3 (10%) 0.09 4.5 mL
PBS (pH 7.2) n/a 500 mL
Total n/a 500 mL
Mix well and sterile filter. Store this solution at 4C for 3 months.
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Amaxa Electroporation Buffer
Reagent Final Concentration (mM) Volume (mL)
NaH2PO4 (1 M) 25.2 0.252
Na2HPO4 (1 M) 64.8 0.648
KCl (1 M) 5 0.05
MgCl2 (1 M) 10 0.1
HEPES (200 mM) 20 1
C4H4Na2O4 (240 mM) 24 1
ddH2O n/a 6.96
Total n/a 10
Mix well in the hood and sterile filter. Store this solution at 4C for 3 months.
Polyethyleneimine (PEI) Solution
Reagent Final Concentration (mg/mL) Volume
PEI (powder) 1 500 mg
ddH2O n/a 500 mL
Total n/a 500 mL
Mix to dissolve at 75C in a water bath, cool down to 25C and adjust pH 7.0 with HCl. Aliquot and store
this solution at -80C.
Dialysis/Concentration Buffer
Reagent Final Concentration Volume (mL)
NaCl (5 M) 50 mM 5
10% Pluronic F68 0.0001% 0.05
PBS (pH 7.2) n/a 500
Total n/a 500
Mix well in the hood and sterile filter. Store this solution at 22C–24C for 6 months.
Balancing Buffer
Reagent Final Concentration (M) Volume (mL)
Tris-HCl pH 8.5 (1 M) 0.01 5
NaCl (5 M) 1 100
PBS (pH 7.2) n/a 500
Total n/a 500
Mix well in the hood and sterile filter. Store this solution at 22C–24C for 6 months.
PBS-MgK Buffer
Reagent Final Concentration (mM) Volume (mL)
MgCl2 (1 M) 1 0.5
KCl (1 M) 2.5 1.25
PBS (pH 7.2) n/a 500
Total n/a 500
Mix well in the hood and sterile filter. Store this solution at 22C–24C for 6 months.
PBS-MgKNa Buffer
Reagent Final Concentration (M) Volume
NaCl (powder) 1 29.22 g
PBS-MgK buffer n/a 500 mL
Total n/a 500 mL
Mix well in the hood and sterile filter. Store this solution at 22C–24C for 6 months.
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15% Iodixanol
Reagent Final Concentration (%) Volume (mL)
OptiPrep 15 7.5
PBS-MgKNa buffer n/a 22.5
Total n/a 30
25% Iodixanol
Reagent Final Concentration (%) Volume (mL)
OptiPrep 25 12.5
PBS-MgK buffer n/a 17.5
Phenol Red 0.25 0.075
Total n/a 30
40% Iodixanol
Reagent Final Concentration (%) Volume (mL)
OptiPrep 40 14.7
PBS-MgKNa buffer n/a 7.3
Total n/a 22
60% Iodixanol
Reagent Final Concentration (%) Volume (mL)
OptiPrep 60 22
Phenol Red 0.45 0.1
Total n/a 22
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of the manufacturer.STEP-BY-STEP METHOD DETAILS
AAV Production
Timing: 5 days
Transfect, harvest and lyse transfected HEK293T cells for AAV production.
1. Maintain HEK293T cells in a 150-mm cell culture dish containing DMEM+/+
(DMEM with high glucose and sodium pyruvate) supplied with 10% FBS
(HEK293T medium) below 80% confluence and harvest at around 80% conflu-
ence.
2. Day 0: Wash cells with PBS and trypsinize with Trypsin-EDTA for 5 min at 37C.
Collect cells by adding 10 mL of fresh HEK293T medium and pipetting up and
down 10 times. Centrifuge at 290 3 g for 5 min at 4C and discard the superna-
tant. Resuspend the cell pellet in 20 mL HEK293T medium and count cell number
using a hemocytometer. Plate 1 3 107 cells in a 150-mm dish in 20 mL HEK293T
medium. For each AAV donor vector, prepare eight 150-mm dishes.
3. Day 1: 2 h before transfection, aspirate the old medium and add 15 mL of fresh
HEK293T medium containing 25 mM HEPES (add 12.5 mL of 1 M HEPES per
500 mL HEK293T medium) to each 150-mm dish containing the HEK293T cells.STAR Protocols--, 100028,--, 2020 7
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Opti-MEM + 10 mg pAAV genome + 10 mg pCap/Rep-DJ + 20 mg pAAV-help-
er plasmids. Gently mix by vortexing and slowly add 120 mL PEI (1 mg/mL) to
the transfection mixture at a 3:1 ratio of PEI (mg): DNA (mg). Vortex briefly and
incubate at 22C–24C for 10 min.
b) Add the transfection mixture dropwise to each 150-mm dish. Mix gently and
transfer the dishes to a cell incubator. Culture the transfected cells at 37C,
5% CO2.
4. Day 2: Aspirate the old medium and add 25 mL of fresh HEK293T medium to each
transfected 150-mm dish. Culture the transfected cells until day 4 for AAV collection.
5. Day 4: Collect the transfected cells using a cell scraper. Transfer medium and cells
from two of the transfected 150-mm dishes to a 50 mL collection tube using a sero-
logical 25mL pipette. Centrifuge at 29003 g for 5 min at 4C and discard the super-
natant. Resuspend the cell pellet in 3 mL PBS and transfer to a 15 mL collection tube.
CRITICAL: The transfection efficiency of three plasmids should be regu-
larly assessed with a pAAV-CMV-GFP-reporter genome plasmid as a
standard.
Note: To avoid bacterial contamination after transfection, we recommend
adding Gentamicin to a final concentration of 10 mg/mL in HEK293T medium
used on day 2.
Pause Point: The cell suspension can be frozen and stored at -80C for later
AAV purification.
6. Prepare a dry ice/ethanol mixture in a foam box and heat up the water bath to
37C.
7. Use three freeze-thaw cycles (10min in the dry ice/ethanol mixture, thenmove to
37C water bath for 10 min) to lyse the cells and release the AAV particles. Vor-
tex the cell suspension thoroughly after each freeze-thaw cycle.
8. After the third freeze-thaw cycle, add Benzonase enzyme to a final concentration
of 100 U/mL and incubate for 1 h at 37C to degrade residual DNA plasmids in
the cell lysate. Mix by inverting occasionally.
9. Add sodium deoxycholate (10% stock solution) to a final concentration of 0.5%.
Add 5 M NaCl to a final concentration of 1 M. Incubate for 30 min at 37C.
10. Centrifuge at 2900 3 g for 30 min at 4C. Transfer the viral supernatant to a
15 mL collection tube.
11. Filter the AAV supernatant through a 0.45 mm PES syringe filter.
12. Finally, pool all the filtered AAV supernatants into a 50 mL collection tube
(~15 mL in total).
CRITICAL: Ensure that the cell suspension is completely frozen and thawed
after each step.
Pause Point: The AAV supernatant can be stored at 4C for 15–18 h and the
ultra-centrifugation performed the next day.
AAV Purification
Timing: 4 h
Prepare iodixanol-containing gradient, ultra-centrifuge and extract AAV particles.8 STAR Protocols--, 100028,--, 2020
Figure 1. Discontinuous, Multilayered Iodixanol Density Gradients for AAV Isolation
15%, 20% 40% and 60% iodixanol solutions are underlaying in an ultra-centrifuge tube and should
look as depicted in the photograph.
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tor by underlaying iodixanol solutions of different concentrations (15%, 25%,
40%, and 60% (see Materials and Equipment)) in a 29.9 mL Beckman Opti-
Seal ultra-centrifuge tube as depicted in Figure 1 (Cabanes-Creus et al., 2019).
a) First, add 6 mL of the 15% iodixanol solution to the bottom of the Beckman tube
using a 10 mL syringe and a long 14-gauge metal needle.
b) Subsequently, underlay 6 mL of the 25% iodixanol solution, by placing the sy-
ringe needle into the bottom of the Beckman tube and gently elute the solu-
tion. Do not puncture the bottom of the tube.
c) Continue the sameway with 5mL of the 40% iodixanol solution and 5mL of the
60% iodixanol solution, respectively.
CRITICAL: Air bubbles inside the syringe will reach the tube and disrupt
the gradient. We recommend tapping the syringe, releasing the iodixanol
solutions slowly and planning for enough dead volume.
Note: ~15 mL of the AAV supernatant (step 12 above) can be split and loaded
equally onto 2 gradient tubes. Fill up the Beckman tube with balancing buffer
to the top of the tubes (Figure 2C) and balance to within 0.01 g difference.
Pause Point: Gradients can be prepared in advance and stored at 4C for
15–18 h.
14. Use a 20-gauge needle to add the cell lysate to the iodixanol gradient tube by
dripping slowly onto the top layer of the gradient (Figure 2A). To avoid disrupt-
ing the gradient, establish a flow along the tube wall as depicted in Figure 2B.
Position the bevel of the needle upwards next to the cap of the tube.STAR Protocols--, 100028,--, 2020 9
Figure 2. Loading Cell Lysate onto Density Gradients for Ultra-centrifugation
(A and B) (A) Cell lysate is loaded on the ultra-centrifuge tube by establishing a flow on the tube
wall. Face the bevel up, hold it close to the tube wall and (B) slowly load the cell lysate along the
tube wall.
(C) Balance the tubes with balancing buffer and seal it with the black cap.
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16. Carefully carry the rotor to a sterile hood and remove the tubes with sterilized
forceps.
17. Prepare a 10 mL syringe with an 18-gauge needle for extracting the AAV-con-
taining 40% iodixanol layer.
18. Carefully clean the tubes with ethanol and a Kimwipe tissue before puncturing
the Opti-Seal tube.
Note: After ultra-centrifugation, different fractions of the cell lysate are sepa-
rated in different iodixanol gradient layers. Proteins and cell debris accumu-
late in 25%-40% interface. The 40% iodixanol layer contains the AAV particles
(Figure 3A).
19. Carefully insert the needle with the bevel up approximately 1–2 mm above the
60% gradient layer to collect the 40% gradient layer containing AAV particles
(Figure 3B).
20. Remove the black cap before extracting the AAV layer.
21. Gradually withdraw 3–5 mL of the AAV-containing layer. After collecting half
of the layer, turn the needle with bevel down to collect the remaining layer
(Figure 3C).
CRITICAL: Be careful during handling and avoid disrupting the gradient
layers. Do not collect the protein-rich interface white band at the interface
of 25% and 40% layers. To avoid contamination with cell debris or proteins
or iodixanol of the 60% iodixanol layer, the 40% AAV-containing layer
should not be collected entirely (Figure 3D).10 STAR Protocols--, 100028,--, 2020
Figure 3. Extraction of the AAV-Containing Layer from the Ultra-centrifuge Tube
(A) Appearance of the different iodixanol gradient after ultracentrifugation.
(B) Insertion of the needle (bevel face up) 1–2 mm above the 60% iodixanol layer.
(C) The remaining volume of the layer is extracted with the bevel face down to prevent
contamination with the protein-rich layer.
(D) Endpoint of extraction (right) compared to before extraction (right).
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sary. For longer storage, store the AAV fraction at -80C.Dialysis of AAV-Containing Iodixanol Solution and AAV Concentration
Timing: 2 days
Dialyze the AAV solution to remove remaining iodixanol and concentrate AAV
particles.
Note: All centrifuge steps are carried out at 2,900 3 g.
22. Prime a 10 k MWCO dialysis cassette by placing the cassette into a container
containing 2 L of dialysis/concentration buffer for 1 minute.
23. Pool AAV extractions from two gradient tubes (~10 mL in total) and filter the
AAV solution through a 0.45 mm PES membrane filter directly into the primed
MWCO dialysis cassette (step 22 above) as depicted in Figure 4A. Before dial-
ysis, the AAV supernatant has a light pink color (Figure 4B).
24. Transfer the AAV-loaded dialysis cassette to the dialysis container and dialyze at
4C for 15–18 h with gentle magnetic stirring at 250–300 rpm (Figure 4C).
25. Use a 20 mL syringe with a 20-gauge needle to collect the AAV solution in the dial-
ysis cassette and transfer it to a 50mL collection tube (Figures 4D and 4E). Now, the
extract from the dialysis cassette should appear transparent (Figure 4E).
CRITICAL: Be careful handling the dialysis cassette and avoid destroying
the dialysis membrane.
Note: If you observe debris in the dialyzed AAV solution, filter again through a
0.45 mm PES syringe filter before starting concentration steps. The maximum
capacity of the dialysis cassette is 12 mL.
Pause Point: After filtration, the dialyzed AAV solution can be stored at 4C
for concentration on the next day.STAR Protocols--, 100028,--, 2020 11
Figure 4. Dialysis of the Extracted AAV-Containing Iodixanol Layer
(A) Injection of the extracted AAV solution from ultra-centrifuge tubes.
(B) The loaded viral solution appears in a light pink color.
(C) The loaded cassette is incubated for 18 h in cold dialysis buffer and magnetically stirred at 200–
300 rpm to exchange iodixanol with dialysis buffer.
(D) Extraction of the cleared AAV-containing solution from the cassette: Hold the cassette vertical
to extract the remaining solution from the corner of the dialysis cassette.
(E) The extracted solution is transferred to a new 50 mL falcon and should appear transparent.
Please cite this article in press as: Tran et al., Protocol for Efficient CRISPR/Cas9/AAV-Mediated Homologous Recombination in Mouse Hemato-
poietic Stem and Progenitor Cells, STAR Protocols (2020), https://doi.org/10.1016/j.xpro.2020.10002826. Prime a 100 K Amicon Ultra-4 centrifuge filter by adding 15 mL of dialysis/concen-
tration buffer to the filter and centrifuge for 5–10 min. Discard the flow-through.
27. Load up to 15 mL of the dialyzed AAV supernatant to dialysis/concentration
buffer-primed 100 K Amicon Ultra-4 centrifuge filter and centrifuge for 10–
15 min. Discard the flow-through and load the remaining AAV supernatant
onto the same Amicon Ultra-4 filter, fill up to 15 mL with dialysis/concentration
buffer and centrifuge for 10–15 min. Discard the flow-through.
28. Wash the AAV particles on the membrane of the Amicon Ultra-4 filter with 15 mL
of dialysis/concentration buffer and centrifuge for 10–15 min. Discard the flow-
through and repeat the washing step two more times.
29. Use a 1000 mL pipette to collect the remaining AAV solution (~200–500 mL) in the
concentrating filter. Pipette up and down several times and transfer the AAV so-
lution to a 1.5 mL Eppendorf tube.12 STAR Protocols--, 100028,--, 2020
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long-term storage. Take a 5 mL AAV aliquot for titration using real-time PCR.
Note: To collect remaining AAV particles, we recommend adding 500–
1000 mL fresh dialysis/concentration buffer to the concentrating filter, pipette
up and down and transfer the AAV solution to the AAV collection tube (step 29
above).
Pause Point: The 5 mL aliquoted AAV can be frozen at -80C before perform-
ing real-time PCR.
Titration of AAV Particles by Real-Time PCR with TaqMan Probes
Timing: 3–4 h
Prepare standard curve using AAV genome plasmid and titrate AAV particles by
TaqMan real-time PCR.
31. Prepare a standard curve using your plasmid stock and adjust it to 2 3 109 mol-
ecules/mL
Example calculation:
We assume that the average molecular weight for a DNA base pair is 650 Da.
Plasmid Size (pAAV-Lmnb1-T2A-mCherry): 7216 bp
Plasmid Concentration: 1 mg/mL
Plasmid Molecular Weight: 7216 bp 3 650 Da/bp (g/mol) = 4.69 3 106 g/mol
Plasmid (mol/mL): 1 (mg/mL) 3 1 (g)/1 3 106 (mg) 3 1/4.69 3 106 (g/mol) = 2.13 3
1 3 1013 (mol/mL)
Plasmid (molecules/mL): 2.13 3 1 3 1013 mol/mL 3 (Avogadro constant)
6.022145 3 1 1023 (molecules/mol) = 1.28 3 1011 molecules/mL
Prepare 100 mL of plasmid with 2 3 109 molecules/mL:
Dilution factor: 1.28 3 1011 (molecules/mL)/2 3 109 (molecules/mL) = 64.2X dilu-
tion
Thus, dilute 1.56 mL plasmid stock with 98.4 mL water (100 mL/64.2=1.56 mL).
32. Prepare a serial 10-fold-stock dilution for the plasmid: 23 108, 23 107, 23 106,
2 3 105, 2 3 104 molecules/mL to create a standard curve by real-time PCR.
33. Prepare DNase I working solution by adding 550 mL of water to 1 stock vial of
DNase I.
34. Prepare a mixture as follows: 10 mL RDD buffer + 2.5 mL DNase I + 5 mL of AAV
and fill up with water up to 100 mL total volume. Incubate at 37C for 30 min. This
will be a 1/20 dilution of the AAV.
35. Serially dilute the AAV 5-fold with water for real-time PCR: 1/100, 1/500, 1/2500
and 1/12500.
36. Prepare a TaqMan real-time PCR reaction as depicted in Table 1.
37. Run the PCR reaction following Table 2.
38. AAV titers are calculated as viral genome copies per mL as described in section
QUANTIFICATION AND STATISTICAL ANALYSIS.
CRITICAL: The standard curve is essential for accurate calculation of AAV
titer. Be careful preparing serial dilution of the AAV genome plasmid.STAR Protocols--, 100028,--, 2020 13
Table 1. Reagents of a Single 20 mL TaqMan Real-Time PCR Reaction
Reagents Final Concentration Volume (mL)
AAV-ITR Forward (10 mM) 0.3 mM 0.6
AAV-ITR Reverse (10 mM) 0.3 mM 0.6
AAV-ITR TaqMan Probe
(10 mM)
0.25 mM 0.5
2X TaqMan Universal PCR
MasterMix
1x 10
AAV or plasmid serial
dilutions
n/a 5
Dnase/Rnase-free water n/a 3.3
Total n/a 20
Tab
St
1
2
3
4
5
14
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ual DNA plasmids in the AAV solution. Run your samples and standard at least
in duplicates and include non-template controls (master mix without tem-
plates or water).Isolation and Culture of Mouse HSPCs
Timing: 3–5 h
Isolate, enrich Sca1+ cells frommouse bonemarrow using MACS separation and cul-
ture isolated HSPCs in vitro.
Note: All centrifuge steps are carried out at 400 3 g for 7 min at 4C.
39. To isolate Sca1+ cells from mouse bone marrow (BM), dissect left and right fe-
murs and tibias from 8–12 weeks old mice. Remove muscles and connective tis-
sue and transfer femurs and tibias to a well of 6-well plate containing 3 mL of
FACS buffer.
40. Use a 1 mL syringe and a 25-gauge needle to flush out the BM from the end of
femurs and tibias, repeat this step several times until the bones become white.
Transfer the BM cell suspension to a 15mL collection tube and wash the well one
time with 5 mL of FACS buffer. Centrifuge the BM cell suspension.
41. Discard supernatant and resuspend the BM cell pellet with 2mL of red blood cell
lysis buffer. Pipette up and down 10 times.
42. Incubate on ice for 5min, subsequently add 10mL of FACS buffer and centrifuge
the BM cell suspension.
43. Discard supernatant, resuspend the BM cell pellet with 2 mL FACS buffer and
mix well by pipetting up and down 10 times. Count total BM cell number using
a hemocytometer before magnetic cell separation (MACS).le 2. PCR Condition for TaqMan Real-Time PCR
ep Temperature Time
50C 2 minutes
95C 10 minutes
95C 15 seconds
60C 1 minutes
Go to step 3 for 39 more times
STAR Protocols--, 100028,--, 2020
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mouse. The following steps of MACS Sca1+ enrichment are described for a
maximum 4 3 107 total BM cells; if working with larger cell number, scale
up all reagents accordingly. Try to keep cells and solutions on ice.
Pause Point: the BM cell suspension can be kept on ice for 1–2 h before pro-
ceeding MACS enrichment.
44. Centrifuge the BM cells and discard the supernatant.
45. Resuspend the BM cell pellet in 382 mL FACS buffer, add 10 mL Fc blocking
antibody (a-mouse CD16/32) to the BM cell suspension, and incubate for
10 min on ice.
46. Add 8 mL a-mouse Sca1-FITC antibody to the BM cell suspension andmix well
by pipetting up and down 10 times. Incubate the Sca1-FITC-labeled BM cells
for 10 min in the dark on ice.
47. Wash the Sca1-FITC-labeled BM cells one time by adding 10 mL of FACS
buffer and centrifuge.
48. Discard supernatant, resuspend the Sca1-FITC-labeled BM cells in 320 mL
FACS buffer and add 80 mL a-FITC MicroBeads to the cell suspension. Mix
well by pipetting up and down several times and incubate for 15 min at
4C in the refrigerator. Mix the cell suspension every 5 min during incubation
by brief vortexing.
49. Wash cells by adding 10mL of FACS buffer and centrifuge. Discard the super-
natant and resuspend the BM cell pellet in 500 mL of FACS buffer.
50. Insert a LS separation column with the column wings to the front into a MACS
separator, insert a 50 mm sterile BD cup-type filcon on top of the LS column.
Rinse the LS column by applying 3 mL of FACS buffer through the BD cup fil-
con to the LS column and let FACS buffer run through. Load 500 mL of the BM
cell suspension through the BD cup filcon into the prepared LS column and
then wash the BD cup filcon two times with 500 mL FACS buffer. Collect the
total effluent (which corresponds to the unlabeled (Sca1) cell fraction) into
a 15 mL falcon tube and set aside for determining the purity of MACS sepa-
ration later.
51. Remove the BD cup filcon and wash the LS column 3 times by adding 3 mL
FACS buffer each time once the LS column reservoir is empty.
52. Remove the LS column from the MACS separator and place it on a 15 mL
collection tube. Pipette 5 mL FACS buffer onto the LS column and immedi-
ately flush out the magnetically labeled cells (Sca1+) by firmly applying the
plunger which is supplied with the column.
53. Count the cells with a hemocytometer.
54. Determine the purity of Sca1+ cell fraction. Stain the BM cells beforeMACS as
well as the Sca1 and Sca1+ cell fractions with a-mouse lineage antibody
cocktail, c-Kit and Sca1 antibodies for 15 min at 4C. Wash the stained cells
with FACS buffer and analyze them using FACS analyzer and FlowJo software
(Figures 5A and 5B).
55. Centrifuge the Sca1+ cells and discard the supernatant. Resuspend the Sca1+
cell pellet in serum-free HPSC medium (StemSpanTM SFEM II medium sup-
plemented with mouse SCF (50 ng/mL), mouse TPO (50 ng/mL), mouse
Flt3-L (50 ng/mL) and human IL-11 (50 ng/mL)) at a density of 2 3 105 cells/
mL. Culture 4 3 105 Sca1+ cells in a well of 6-well plate in total volume of
2 mL.STAR Protocols--, 100028,--, 2020 15
Figure 5. FACS Plots Showing LinSca1+c-Kit+ (LSK) Cell Fractions after MACS Purification and
2 Days of Culture
Bone marrow cells were stained with a-mouse lineage cocktail, Sca1, and c-Kit antibodies.
(A) The negative fraction of the LS column should be almost completely depleted of Sca1+ cells.
(B) The positive fraction eluted from the LS or MS separation column is enriched in LSK cells and
progenitor cells, which all express Sca1. The LSK population should comprise 6 to 8% of the Sca1+
cell fraction. Lymphoid progenitor cells require IL-7 to survive and will be depleted upon culturing
with 50 ng/mL mTPO, mSCF, mFLT-3, and hIL-11.
(C) Purified LSK cell fraction after 2 days of culture in HSPC medium.
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(1 mL) to a well of 6-well plate and add 1 mL HSPC medium to reach 2 mL per
well.
57. Determination of the proliferation rates of cultured HSPCs (optional)
a) Wash 13 106 Sca1+ cells (step 53 above) two more times by adding 10 mL
of PBS and centrifuge. Resuspend the cell pellet in 1 mL of PBS, add Cell-
Trace violet to a final concentration of 5 mM and pipette up and down 10
times. Label these cells at 37C for 15 min in the dark.
b) Wash the labeled cells by adding 10 mL of serum-free StemSpanTM SFEM
II medium and centrifuge.
c) Follow steps 55 to 56 above for culturing and passaging mouse HSPCs in
HSPC medium.
d) After 48 h of CellTrace labeling, the proliferative activity of the cultured
HSPCs is determined by flow cytometry.CRITICAL: It is important to maintain mouse HSPCs at low density (% 2 3
105/mL) to obtain high HR efficiency and high survival rates.
Note: In order to increase the efficiency of Sca1+ MACS enrichment, we
recommend repeating the magnetic separation procedure from steps 49 to
52 with a new column. Depending on cell yield, the eluted fraction from
step 52 should be further enriched over a MS (smaller capacity) or a LS column
(larger capacity).
Pause Point: After passaging, the cultured HSPCs are placed back into cell
incubator for further 24 h.CRISPR/Cas9/AAV-Mediated HR in Mouse HSPCs
Timing: 2–3 h
Insert the coding sequences of the self-cleavage peptide T2A coupled to the fluores-
cent marker mCherry (T2A-mCherry) in-frame into the last exon of the mouse Lamin
B1 (Lmnb1) gene in mouse HSPCs.
Note: All centrifuge steps are carried out at 400 3 g for 5 min at 22C–24C.
58. Collect the activated HSPCs by pipetting up and down 10 times and trans-
fer to a 15 mL collection tube after 48 h of culture. Determine the cell con-
centration using a hemocytometer and centrifuge the activated HSPCs.
Discard the supernatant and wash the activated HSPCs one time with
22C–24C PBS by resuspending in 10 mL PBS and centrifuge. Remove
the supernatant and resuspend the cell pellet in Amaxa electroporation
buffer at a density of 2–3 3 105 HSPCs per 20 mL. Follow step 59 for HSPCs
isolated from Cas9 transgenic mice or step 60 for isolated from C57BL/6
mice.
59. Gene editing in Cas9 transgenic-derived HSPCs: due to constitutive Cas9
expression, only the delivery of sgRNA is required for gene targeting.
a) Transfer 20 mL cell suspension in Amaxa electroporation buffer (total
2–3 3 105 cells) in step 1 to a 1.5 mL Eppendorf tube.
b) Add 100 pmol sgRNA to the cell solution. Mix well by pipetting up and
down 10 times and continue with step 61 below.STAR Protocols--, 100028,--, 2020 17
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(RNP) complexes are required for gene editing.
a) Per reaction/electroporation, mix 50 pmol wild-type SpCas9 protein (from
IDT or produced in-house) with 100 pmol sgRNA (Synthego or IDT),
and incubate 10 min at 22C–24C.
b) Transfer 20 mL cell suspension in Amaxa electroporation buffer (total 2–33 105
cells) in step 1 to a 1.5 mL Eppendorf tube.
c) Add CRISPR/Cas9 RNP complexes to the cell suspension. Mix well by pipetting
up and down 10 times and continue with step 61 below.
61. Transfer 20 mL electroporation mixture to a well of a 16-well Nucleocuvette
strip.
62. Electroporate the cassette in the Amaxa 4D-Nucleofector with the
‘‘mouse B cell program’’ provided by the manufacturer.
63. Add 80 mL of pre-warmed HSPC medium to the well of the electroporation
cassette to collect electroporated HSPCs. Transfer the electroporated HPSCs
to a well of a 12-well plate containing 1 mL pre-warmed HSPC medium.
64. Transfer 104 electroporated HSPCs to a well of a 48-well plate containing
500 mL HSPC medium. 30 min later, infect the electroporated HSPCs with
AAV-DJ carrying the donor template at a MOI of 5 3 106 genome copies
per cell. Place AAV-infected HSPCs back into the incubator.
65. Two days post editing, collect the targeted HSPCs by pipetting up and down,
pool together into a 15 mL collection tube and count cell number with a he-
mocytometer. 20% of total targeted HSPCs are saved for analyzing HR effi-
ciency by flow cytometry (continue step 66 below) or PCR amplification and
sequencing (continue step 67 below). The remaining cells can be used for
transplantation to assess engraftment efficiency of the targeted HSPCs in
vivo.
CRITICAL: To minimize cell death due to electroporation, do not use
expired electroporation buffer. The AAV volume should not exceed 20%
of the total volume.
Note: Depending on the experimental set up, the number of the electropo-
rated HSPCs infected with AAV donor vectors can be scaled up accordingly.
Note: After 48 h of culture in HSPC medium, mouse HSPCs should have
increased in size and formed cell clusters indicating proliferation. During es-
tablishing gene knockin experiments in mouse HSPCs, try to use different
AAV MOI numbers in order to optimize HR efficiency. Include the following
controls for testing HR efficiency: 1) only electroporated, 2) only infected
with AAV-DJ, and 3) only sgRNA-electroporated cells without AAV-DJ.
Pause Point: For quantification of HR and NHEJ events by PCR amplification
and sequencing, 20% of the total targeted HSPCs are collected by centri-
fuging and the cell pellet can be stored at -20C for several days before ex-
tracting genomic DNA.
Evaluation of HR Efficiency
Timing: 2–48 h
Determine HR efficiency by flow cytometry (mCherry+ cells) or quantify of HR and
NHEJ events in the targeted Lmnb1 locus by PCR amplification and sequencing.18 STAR Protocols--, 100028,--, 2020
Please cite this article in press as: Tran et al., Protocol for Efficient CRISPR/Cas9/AAV-Mediated Homologous Recombination in Mouse Hemato-
poietic Stem and Progenitor Cells, STAR Protocols (2020), https://doi.org/10.1016/j.xpro.2020.100028Note: All centrifuge steps are carried out at 400 3 g for 5 min at 4C.
66. Determination of HR efficiency by flow cytometry:
a) 20% of the total targeted HSPCs (step 65 above) are transferred to a FACS
tube and centrifuged.
b) Discard the supernatant, wash the targeted HSPCs with 1 mL PBS and
centrifuge. Discard the supernatant, resuspend the HSPCs in 100 mL
FACS buffer containing Fc blocking antibody (a-mouse CD16/32, diluted
1:250) and incubate at 4C–8C for 10 min.
c) Add the stem cell antibody staining cocktail (a-mouse lineage-cocktail, c-Kit,
Sca1, CD48 and CD150) to the FACS tube and incubate at 4C–8C for
15 min.
d) Add 1 mL FACS buffer to the FACS tube and centrifuge. Discard thesupernatant and wash the cells by adding 1 mL FACS buffer to theFACS tube. Centrifuge the cells and discard the supernatant. Finally, re-
suspend the stained HSPCs in 200–300 mL FACS buffer containing 1 mg/
mL DAPI for flow cytometric analysis.
e) The stained HSPCs are analyzed in a BD Fortessa analyzer with the flow
rate setting in slow mode.
f) Export and analyze the raw data using FlowJo software. Frequencies of
mCherry+ cells are determined in all cell fractions (Lineage (Lin)Sca1+
c-Kit+ (LSK), HSC/multipotent progenitor (MPP)1, MPP2, MPP3/4).
67. Quantification of HR and NHEJ events by PCR amplification and sequencing:
a) 20% of the total targeted HSPCs (step 65 above) are transferred to a
1.5 mL Eppendorf tube and centrifuged.
b) Discard the supernatant and wash the cells by adding 1 mL PBS to the
collection tube. Centrifuge the cells and discard the supernatant. Resus-
pend the cell pellet in QuickExtractTM DNA Extraction Solution at a den-
sity of 104 cells/10 mL.
c) Mix well and briefly vortex to completely lyse cells. Transfer a maximum of
100 mL lysed cells into a PCR tube.
d) Denature genomic DNA by following thermal cycle: 65C for 15 min, 68C
for 15 min, 95C for 15 min and 4C using a PCR machine. The denatured
genomic DNA is ready for PCR amplification.
e) Perform PCR amplification using primer sets binding outside of the HAs
(see step 3 in section Before You Begin) and LongAmp PCR master mix
or alternative DNA polymerases (KOD hot start DNA polymerase) for
long-range PCR.
f) Run PCR products on 1%–2% agarose gel and take a photograph. HR
bands are larger than the NHEJ or wild-type (WT) bands which have
similar size.
g) Band quantification can be performed using the free ImageJ software
(Schneider et al., 2012). HR efficiency is estimated on the basis of band
intensity.
h) HR and NHEJ/WT bands are extracted from the gel and cloned into pJET
plasmids using the CloneJET PCR cloning kit. PCR colonies are sequenced
by Sanger sequencing. Basing on the nucleotide sequences of the targeted
loci, the relative frequencies of HR, NHEJ and WT events are determined.EXPECTED OUTCOMES
Using this step-by-step protocol, we routinely produce up to total 8 3 1013 viral
genome copies from eight 150-mm dishes of transfected HEK293T cells. For long-STAR Protocols--, 100028,--, 2020 19
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100 mL volumes and stored at -80C. After thawing, the remaining AAV solution
can be stored at -20C for one month.
The purity of the Sca1+ cell fraction after MACS enrichment should be ~95%–97%.
~10% of the cells in the Sca1+ cell fraction are LSK cells. Two days post stimulation
with stem cell cytokines, the LSK cell compartment should have expanded to up to
80%–90% (Figure 5C). Normally, we achieve up to 1 3 106 LSK cells isolated from a
mouse after 2 days in vitro culture.
In our hands, this step-by-step protocol for gene knockin and gene repair in mouse
HSPCs routinely achieves efficient HR (~25%–30%) in several gene loci by using
CRISPR/Cas9 in combination with AAV-DJ to deliver the donor templates. Screening
other AAV serotypes might help to further increase HR efficiency in mouse HSPCs. In
addition, the inhibition of the NHEJ pathway by small inhibitors might also improve
HR efficiency in mouse HSPCs.
Our system is suitable to model blood disorders that are caused by mutations in
more than one gene. Our protocol allows the simultaneous targeting of multiple
gene loci in mouse HSPCs. In Tran et al. (2019), we inserted in-frame coding se-
quences of T2A-mCherry and T2A-BFP reporters into the last exon of the Lmnb1
and beta-actin (Actb) genes, respectively. We obtained approximately 3.5% of dou-
ble-positive LSK cells expressing both mCherry and BFP reporters.
Upon transplantation into irradiated immunodeficient mice, the targeted HSPCs
engraft efficiently and fully reconstitute the hematopoietic system with all immune
cell lineages detected in the bone marrow and spleen of the transplanted animals
at 8- or 16-weeks post reconstitution (see Tran et al., 2019).QUANTIFICATION AND STATISTICAL ANALYSIS
Calculation of AAV Titers
We typically use the following procedure to calculate AAV titers in viral genome
copies per mL using the standard curve.
1. Calculate the average of the CT-value of each plasmid and AAV-dilution from
step 38.
2. Prepare a standard curve from the 5 plasmid dilutions.
3. Calculate a linear regression (y=mx+c) and determine the coefficient of determi-
nation (R2). R2 should be >0.98. An exemplary graph is shown in Figure 6.
4. Use slope (m) and intersection of the y-axis (c) to calculate x=(y-c)/m. Y is the
average CT of each AAV-dilution.
5. Example according to values given in Figure 6: x= (averageCT- 42,049)/-3,4218
6. Calculate 10x for each serial AAV-dilution.
7. Multiply the value by the dilution factor for each serial AAV-dilution.
8. Average all values to calculate the real AAV-titer.LIMITATIONS
One important limitation of this protocol is the maximal AAV packaging capacity of
4.5 kb. However, within these limits we successfully performed targeted insertions of
0.8 kb reporters into the Lmnb1 and beta-actin (Actb) loci and replaced a neomycin
cassette of 2 kb with a Rag2 wild-type sequence of 0.8 kb. Furthermore, maximal HR20 STAR Protocols--, 100028,--, 2020
Figure 6. Generation of Standard Curve for Calculating AAV Titer Using TaqMan Real-Time PCR
CT values from serial dilution of the AAV genome plasmid are represented on the y-axis. The
dilution factor of the diluted plasmid is represented as log10 value on the x-axis.
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poietic Stem and Progenitor Cells, STAR Protocols (2020), https://doi.org/10.1016/j.xpro.2020.100028in HPSCs is dependent on cellular proliferation activity, because only cells in S and
G2 phase preferentially use the HR pathway. Enriched mouse Sca1+ cells are a het-
erogeneous population including true stem cells and various differentiating progen-
itor cell subsets. In our culture conditions, the HSC andMPP1 LSK subsets proliferate
more slowly than themore differentiatedMPP2 andMPP3/4 LSK subsets. As a result,
HR efficiency in the HSC and MPP1 subsets is lower (~10%) compared to the MPP2
and MPP3/4 subsets (up to 30%) (Tran et al., 2019).
TROUBLESHOOTING
Problem
Low quality of purified AAV donor vectors can lead to low HR efficiency and low sur-
vival of mouse HSPCs. Furthermore, AAV infection causes induction of cell death and
proliferation arrest in mouse HSPCs.
Potential Solution
Low quality of purified AAV batches may be due to unhealthy HEK293T cells, trans-
fection failure or incomplete HEK293T cell lysis. First, low passage (<15 passages)
mycoplasma-free HEK293T cells should be used. Second, the transfection efficiency
of the three plasmids (AAV production, step 3) should be regularly assessed with a
pAAV-CMV-GFP-reporter genome plasmid as a standard. Third, the transfected
HEK293T cells must be completely lysed in order to obtain high amounts of AAV par-
ticles. Lysis efficiency can be monitored in parallel to an experiment with pAAV-
CMV-GFP transfected HEK293T cells as the supernatant turns light green after three
freeze/thaw cycles. We recommend to carefully determine the AAV titers by real-
time PCR and to test each AAV batch with mouse HPSCs for efficient HR and low
toxicity. Notedly, the AAV volume is kept below 20% of the total culture volume.
Problem
Contamination of residual DNA plasmids in the purified AAV solutionmay negatively
influence the survival of mouse HSPCs and results of AAV titration by real-time PCR.STAR Protocols--, 100028,--, 2020 21
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In order to remove residual DNA plasmids in the purified AAV solution, the amount
of Benzonase (per 1 mL cell lysate) should therefore be scaled according to the num-
ber of 150-mm dishes combined into one 15 mL collection tube (step 5). We recom-
mend adjusting the Benzonase units per mL of the cell lysate as follows: 2 dishes:
50 U/mL, 4 dishes: 100 U/mL or 8 dishes: 200 U/mL. In addition, digesting time
with Benzonase can be carried out at 37C for 2 h.Problem
Low survival of the electroporated HSPCs can be caused by expired electroporation
buffer.Potential Solution
To avoid this problem, the electroporation buffer must be filtered before use and
stored no longer than 3 months at 4C. In addition, screening of different electropo-
ration programs might be useful to enhance the gene editing efficiency.Problem
LowHR efficiency due to low proliferative activity and quality of the activated HSPCs.Potential Solution
The HR pathway is active during the S and G2 phases of the cell cycle. In order to
maximize HR efficiency, we thus recommend that before performing knockin exper-
iments the proliferative activity of mouse HSPCs should bemonitored by flow cytom-
etry (see step 57). The Sca1+ cell fraction obtained by MACS contains only 10% LSK
cells that respond to stem cell cytokines, while 90% of the Sca1+ progenitor cells
remain unresponsive, undergo apoptosis and become toxic to neighboring LSK
cells. Therefore, we recommend using a dead cell removal kit (Miltenyi Biotec) dur-
ing HSPC culture (Steps 55 to 56). In addition, we suggest that mouse HSPCs are
cultured at a low density of 2 3 105 cells/mL to minimize toxicity from dying cells.ACKNOWLEDGMENTS
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